Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Science · 29.03.2024 · 383 (6690) · 1434-1440
DOI: 10.1126/science.adm9724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 29.03.2024. Verfasst von Bin Tan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA. Hauptthemen laut MEDLINE: Coronavirus Papain-Like Proteases, COVID-19, SARS-CoV-2, Coronavirus Protease Inhibitors. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral antivirals. The SARS-CoV-2 papain-like protease (PL pro ) is a promising but challenging drug target. We designed and synthesized 85 noncovalent PL pro inhibitors that bind to a recently discovered ubiquitin binding site and the known BL2 groove pocket near the S4 subsite. Leads inhibited PL pro with the inhibitory constant K i values from 13.2 to 88.2 nanomolar. The co-crystal structures of PL pro with eight leads revealed their interaction modes. The in vivo lead Jun12682 inhibited SARS-CoV-2 and its variants, including nirmatrelvir-resistant strains with EC 50 from 0.44 to 2.02 micromolar. Oral treatment with Jun12682 improved survival and reduced lung viral loads and lesions in a SARS-CoV-2 infection mouse model, suggesting that PL pro inhibitors are promising oral SARS-CoV-2 antiviral candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA.
- Department Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA.
- Center for Advanced Biotechnology and Medicine, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA.
- Department of Chemistry and Chemical Biology, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA.
- Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA.
- Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, OK 74078, USA.
ORCID-Profile: Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, Prakash Jadhav, Haozhou Tan, Xiang Chi, Francesc Xavier Ruiz, Eddy Arnold, Xufang Deng, Jun Wang
Förderung
- NIAID NIH HHS
Zitieren
APA
Tan, B., Zhang, X., Ansari, A., Jadhav, P., Tan, H., Li, K., Chopra, A., Ford, A., Chi, X., Ruiz, F. X., Arnold, E., Deng, X., & Wang, J. (2024). Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science, 383(6690), 1434-1440. https://doi.org/10.1126/science.adm9724
Vancouver
Tan B, Zhang X, Ansari A, Jadhav P, Tan H, Li K, et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024;383(6690):1434-1440. doi:10.1126/science.adm9724
BibTeX
@article{Tan2024,
author = {Tan, Bin and Zhang, Xiaoming and Ansari, Ahmadullah and Jadhav, Prakash and Tan, Haozhou and Li, Kan and Chopra, Ashima and Ford, Alexandra and Chi, Xiang and Ruiz, Francesc Xavier and Arnold, Eddy and Deng, Xufang and Wang, Jun},
title = {Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model},
journal = {Science},
year = {2024},
volume = {383},
number = {6690},
pages = {1434--1440},
doi = {10.1126/science.adm9724}
}
EUVIMED